IP Library › Granted Patent US 7,893,068
Granted Patent B2
US 7,893,068 · App. 11/927,564 · Granted Feb 22, 2011

Physiologically active substances

Assignees: Mercian Corporation; Eisai R&D Management Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,893,068
App. No.
11/927,564
Granted
Feb 22, 2011
Kind
B2
Abstract

The present invention relates to a compound represented by the formula (I): (wherein, R 3 , R 6 , R 7 and R 21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

Claims (4)

1. (8E,12E,14E)-7-((4-Cycloheptylpiperazin-1-yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide, or a pharmacologically acceptable salt thereof.

2. A compound having the structure:

or a pharmacologically acceptable salt thereof.

3. A pharmaceutical composition, comprising the compound or the pharmacologically acceptable salt thereof according to claim 1 or 2 as an active ingredient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2012
From: MERCIAN CORPORATION
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 027691/0440 →
Priority Claims (3)
JP 2002-155853 · May 29, 2002 · national
JP 2002-223355 · Jul 31, 2002 · national
JP 2003-063176 · Mar 10, 2003 · national
Continuity (3)
Continuation 11473201 · Jun 23, 2006
Continuation In Part 10515647 · Jul 20, 2005
Related Publication 20080255146A1 · Oct 16, 2008